# Oculis Holding AG (OCS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $12.17, market value $676 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Oculis Holding AG reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.8×**. The shares trade at 2.8× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -12.0%** (5-yr avg -32.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -50.5%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 10.8%**. Earnings per share rose 10.8%.

## Financial health
- **Current ratio: 5.96** (quick 5.96). Current assets cover the next year's liabilities 5.96 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Oculis Holding AG does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (10 analysts). 10 analysts cover Oculis Holding AG; the consensus is strong_buy, with an average price target of $36.03 (+196% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -29.1%** (YTD -39.1%, 3-mo 8.6%). The shares are down 29.1% over twelve months including dividends.
- **From 52-week high: -64.7%** (15.7% above the low). Trading 65% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 42**. An RSI of 42 is neutral.
- **Beta (1 yr): 0.98** (volatility 65%). Beta of 0.98 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=OCS · Page: https://foliofundamentals.com/stocks/ocs

Not investment advice.